$WEYS

Weyco Stock Rise 13% Despite Q3 Earnings Down Y/Y on Tariffs

WEYS' Q3 earnings slip 18% year over year amid tariff pressures and softer consumer demand. Management is shifting sourcing strategies and declared a special $2 dividend alongside its regular payout.

Original reporting
Zacks Commentary · Zacks Equity Research
Published Nov 10, 2025, 6:20 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 11, 2025, 1:01 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Weyco Stock Rise 13% Despite Q3 Earnings Down Y/Y on Tariffs — source image
Decision brief

The 30-second read

$WEYSNeutralMed
01

Why it matters

Market reacted positively to the dividend announcement, resulting in a 13% stock increase despite earnings decline, indicating investor focus on shareholder returns.

02

Market read

The news is moderately relevant for retail sector traders, especially those focusing on dividend strategies and operational shifts.

03

What to watch

Potential impact of tariffs on future earnings and consumer demand trends; management's ability to execute sourcing strategies effectively.

Timing: short-term

Background

Weyco reported an 18% decline in Q3 earnings amid tariff pressures and softer consumer demand, prompting strategic sourcing shifts and a special dividend declaration.

Company-level read

Ticker impact

$WEYSNeutralMedium confidence
Context

The news pertains directly to Weyco Group Inc. (WEYS), highlighting a significant stock price movement despite earnings decline, which is relevant for traders monitoring this ticker.

Expected impact

Short-term volatility with potential upward correction; stock may experience a rally due to positive market reaction to dividend announcement.

Evidence & confidence

The stock's rise despite earnings decline indicates market optimism possibly driven by dividend news and strategic shifts, but underlying earnings weakness tempers confidence.

Market effects

The retail and wholesale sector may see increased investor interest due to Weyco's dividend strategy and operational adjustments.

Limited regional impact; effects are contained within the US retail sector.

Negligible; Weyco is a regional player with limited global exposure.

Counterpoint

The stock's rise may be a short-term reaction to dividend news, with underlying earnings weakness potentially leading to a correction. Caution advised.

Key entities

  • Weyco Group Inc.

    A regional footwear retailer and wholesaler.

Related articles

$WEYSMed

Weyco Group (WEYS) Q2 2026 Earnings Call Transcript

Weyco Group (WEYS) reported Q2 2026 net sales of $62.2 million, up 7%, and net earnings of $13.3 million. Diluted EPS was $1.39 versus $0.24 a year earlier, helped by $15.3 million tariff refunds recognized after the U.S. Supreme Court invalidated certain tariffs. Wholesale net sales rose 7% to $48.8 million; cash was $98.1 million with no debt.

$WEYSMed

Weyco Group, Inc. Q2 2026 Earnings Call Summary

Weyco Group, Inc. reported Q2 2026 results boosted by $15.3 million in tariff refunds after a U.S. Supreme Court ruling invalidated prior IEEPA levies, plus 7% wholesale growth led by Florsheim. Management plans to raise inventory to about $70 million by year-end amid tariff uncertainty, including incremental tariffs of 12.5% on imports from China, Dominican Republic and Vietnam.

$WEYSMed

WEYCO GROUP INC (WEYS): Results of Operations and Financial Condition

WEYCO GROUP INC (WEYS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 WEYCO REPORTS SECOND QUARTER 2026 RESULTS ​ ​ Milwaukee, Wisconsin---August 4, 2026---Weyco Group, Inc. (NASDAQ: WEYS) (“we,” “our,” “us” and the “Company”) today announced financial results for the quarter ended June 30, 2026. ​ Second Quarter 2026 Overview ● Net sa

$MSFTHigh

Prediction: Microsoft Could Be the Next $5 Trillion Stock

Microsoft (MSFT) received a BUY rating and $600 price target from 24/7 Wall St., citing 43% Azure growth and a $678B commercial RPO backlog. The stock is up 27.81% over the past month and 3.29% year-to-date, with Q4 FY26 revenue of $90.01B and non-GAAP EPS of $4.74. The target implies 18.9% upside, potentially pushing market cap to $5T. Bulls highlight demand outpacing supply, while bears note capital intensity and declining PC revenue.

$LLYMedAI 9/10

FRI AM News: WisBusiness: the Podcast with Serafino Fabiano, Eli Lilly and Company; State joins lawsuit targeting Trump administration over family planning funding

Eli Lilly and Company's Kenosha facility, acquired in 2024, is part of a $4 billion investment in Wisconsin for injectable medicine production. The site, which received FDA approval in 18 months, is producing drugs like Zepbound and Mounjaro. The facility is expected to support 750 jobs and has attracted attention due to its strategic location and skilled workforce. Wisconsin has also joined a lawsuit against the Trump administration's family planning funding rules. The state collected $450.8 mi